White House: 'Cures' bill responsibilities exceed FDA resources
This article was originally published in Scrip
Before lawmakers got into the serious business of considering nearly 30 amendments to the 21st Century Cures Act (HR 6) on 8 July, there was a lot of camaraderie and even some brotherly love being shared – a "bromance" that nearly brought the House Rules Committee chairman, Representative Pete Sessions (Republican-Texas), to tears in expressing his fondness for the bill's lead author, Representative Fred Upton (Republican-Michigan).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.